Our Speakers



Our Speakers

 Randolf	Kerschbaumer
Randolf Kerschbaumer

Founder and Managing Director, OncoOne, Austria

Anat	Globerson
Anat Globerson

Laboratory Manager and Senior Scientist, Tel Aviv Sourasky Medical Center, Israel

Ann White
Ann White

Senior Principal Scientist, UCB Celltech

Anneli Andersson
Anneli Andersson

Scientific Project Manager, Nebion, Switzerland

Annelise 	Vuidepot
Annelise Vuidepot

VP, Head of Oncology Pipeline and Research, Immunocore

Brian Champion
Brian Champion

CSO, PsiOxus Therapeutics

Carlo Boutton
Carlo Boutton

Director Technology & Information Management, Ablynx, Belgium

Cesar Evaristo
Cesar Evaristo

Miltenyi Biotec,Team Coordinator, Germany

Christian Kellner
Christian Kellner

Group Leader, University of Kiel

Daniel O' Connor
Daniel O' Connor

CEO, OncoSec

Daniel O' Connor
Daniel O' Connor

CEO, OncoSec, USA

Dario Neri
Dario Neri

Professor, Department of Chemistry and Applied Biosciences,Swiss Federal Institute of Technology Zurich

David	Gilham
David Gilham

Vice President, R&D, Celyad

Delphine Boulanger
Delphine Boulanger

Business Development Manager, PX-Therapeutics, France

Eitan Yefenof
Eitan Yefenof

Full Professor, Department of Immunology, The Hebrew University of Jeruselum

Eric 	Borges
Eric Borges

VP, Cancer Immunology & Immune Modulation, Boehringer Ingelheim

Eugene Zhukovsky
Eugene Zhukovsky

Chief Scientific Officer, Biomunex Pharmaceuticals

Ezio Bonvini
Ezio Bonvini

Senior Vice President, Research & Chief Scientific Officer, MacroGenics

MacroGenics

Farzin Farzaneh
Farzin Farzaneh

Professor of Molecular Medicine, King's College London, UK

Frank Walsh
Frank Walsh

CEO

Ossianix

Graham Pawelec
Graham Pawelec

Professor of Experimental Immunology, University of Tuebingen

Gregory 	Driessens
Gregory Driessens

Head of In Vivo Pharmacology, iTeos Therapeutics, Belgium

Gundram	Jung
Gundram Jung

Professor, Head of Experimental Antibody Therapy, University of Tübingen

Jeanette	Leusen
Jeanette Leusen

Group Leader, Laboratory for Translational Immunology, UMC Utrecht

Jeffery Pollard
Jeffery Pollard

Director of the MRC Centre for Reproductive Health, University of Edinburgh

Katy Everett
Katy Everett

Senior Scientist, F-Star, UK

Kevin Hollevoet
Kevin Hollevoet

Head, Antibody Gene Transfer Program, KU Leuven

Liselotte Brix
Liselotte Brix

Chief Scientific Officer, Immudex, USA

Lolke de Haan
Lolke de Haan

Senior Director R&D, Toxicology, Global Immuno-Oncology Nonclinical Safety Lead,MedImmune

Mark Cragg
Mark Cragg

Professor of Experimental Cancer Research, University of Southampton

Mark Throsby
Mark Throsby

EVP & CSO, Merus

Markus Zettl
Markus Zettl

Director, Immuno-Oncology, Pieris Pharmaceuticals

Marta Kijanka
Marta Kijanka

Interim CEO, APO-T, Netherlands

Michael Stark
Michael Stark

President, NESA, Germany

Pamela Bogner
Pamela Bogner

Scientist PKDM, Amgen, Germany

Philip Beer
Philip Beer

Visiting Scientist, Sanger Institute, UK

Robert Boyd
Robert Boyd

UK Site Head and Scientific Director,Oxford BioTherapeutics

Robert Hawkins
Robert Hawkins

Professor & Medical Oncologist, University of Manchester

Roland Kontermann
Roland Kontermann

Deputy Head of Biomedical Engineering, University of Stuttgart

Rupert Kenefeck
Rupert Kenefeck

Group Leader, Immunocore, UK

Saeed Rafii
Saeed Rafii

Medical Director,Roche

Sophia Karagiannis
Sophia Karagiannis

Head of Cancer Antibody Discovery and Immunotherapy ,King's College London

Stefan Gluck
Stefan Gluck

Vice President, Global Medical Affairs Solid Tumors, Immuno-Oncology and Early Assets, Clegene

Celgene

Steve Anderton
Steve Anderton

Group Head of Translational Biology, Aquila BioMedical, UK

Thierry Wurch
Thierry Wurch

Director, External Research & Innovation, Immuno-oncology, Servier

Thomas	Carter
Thomas Carter

University College London, UK

Ulrike  Gnad-Vogt
Ulrike Gnad-Vogt

CMO, CureVac

Xavier Chauchet
Xavier Chauchet

Head, In Vivo Pharmacology, NovImmune, Switzerland

Zelig Eshhar
Zelig Eshhar

Professor, Weizmann Institute of Science


Loading...